Impact of Bariatric Surgery on End-Stage Liver Disease Incidence: Nordic Cohort Study

Overview

This large population-based cohort study across four Nordic countries assessed the impact of bariatric surgery on the risk of developing end-stage liver disease (ESLD) in adults with obesity. Findings indicate that bariatric surgery is associated with a significantly reduced incidence of ESLD and lower mortality related to ESLD compared to non-operative care.

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among individuals with morbid obesity and is a leading cause of end-stage liver disease. Weight loss is the primary recommendation to prevent progression of MASLD, but no specific pharmacologic treatments exist. Bariatric surgery offers substantial and sustained weight loss and has been shown to improve liver histology in MASLD. However, concerns exist regarding potential increased substance addiction post-surgery, which could worsen liver outcomes. Prior studies on bariatric surgery's effect on long-term ESLD risk have been limited and inconclusive.

Data Highlights

Key Findings

• Bariatric surgery was associated with a 59% reduction in the risk of developing end-stage liver disease compared to non-operative management in adults with obesity.
• Mortality related to end-stage liver disease was 44% lower in patients who underwent bariatric surgery.
• The study included over three decades of follow-up data from national registries in Denmark, Finland, Norway, and Sweden, ensuring robust and comprehensive data capture.
• Gastric bypass was the predominant bariatric procedure analyzed and contributed significantly to the observed protective effect.
• Patients with prior excessive alcohol use or other liver diseases were excluded to isolate the effect of bariatric surgery on MASLD-related outcomes.

Clinical Implications

Bariatric surgery should be considered a valuable intervention for patients with morbid obesity to reduce the risk of progression to end-stage liver disease. Clinicians should weigh the benefits of substantial weight loss via surgery against potential risks, with current evidence supporting surgery's protective role in liver-related outcomes. Long-term monitoring post-surgery remains important to manage any emerging complications.

Conclusion

This comprehensive Nordic cohort study demonstrates that bariatric surgery significantly lowers both the incidence and mortality of end-stage liver disease in adults with obesity. These findings support bariatric surgery as an effective strategy to mitigate severe liver disease progression in this high-risk population.

References

1. NordOSCo Study Group 2024 -- Impact of Bariatric Surgery on the Incidence of End-Stage Liver Disease